Cover Image
市場調查報告書

美國·歐洲的骨形成蛋白 (BMP) 成長因素療法市場:16個國家 (2011年∼2021年)

US & Europe Markets for Bone Morphogenetic Protein Growth Factor Therapy - 16 Countries (2011-2021)

出版商 iData Research Inc. 商品編碼 338823
出版日期 內容資訊 英文 62 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國·歐洲的骨形成蛋白 (BMP) 成長因素療法市場:16個國家 (2011年∼2021年) US & Europe Markets for Bone Morphogenetic Protein Growth Factor Therapy - 16 Countries (2011-2021)
出版日期: 2015年07月01日 內容資訊: 英文 62 Pages
簡介

骨形成蛋白 (BMP) 是誘導骨折後的骨頭形成的成長因素。

本報告提供美國·歐洲的骨形成蛋白 (BMP) 成長因素療法市場相關調查分析,提供您市場概要,國家概況,各產品的市場分析與預測,推動市場要素與阻礙要素,競爭分析等系統性資訊。

第1章 調查手法

  • 調查範圍
  • 調查手法

第2章 歐洲的國家概況

  • 簡介
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 荷比盧三國
  • 斯堪地那維亞
  • 奧地利
  • 瑞士
  • 葡萄牙

第3章 歐洲的BMP成長因素療法市場

  • 簡介
  • 市場分析與預測
  • 推動市場要素與阻礙要素
  • 競爭分析

第4章 美國的BMP成長因素療法市場

  • 市場分析與預測
  • 推動市場要素與阻礙要素
  • 競爭分析

簡稱

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: iDATA_USEUBMP15_RPT

Bone morphogenetic proteins (BMPs) are growth factors that induce the formation of bone after a fracture. In nature, these proteins have a critical role during embryonic development in the formation of the skeleton. There are twenty different BMPs that have been discovered thus far, of which only two, BMP-2 and BMP-7, have been commercialized as bone graft substitutes for use in specific orthopedic procedures. The commercial versions of these products are produced by recombinant genetic engineering, which results in a recombinant human protein. The recombinant human BMP-2 (rhBMP-2) is marketed as a commercial product by Medtronic, Inc. and is called Infuse® (InductOS® in Europe), while BMP-7 has been commercialized by Stryker Inc. and is sold to Olympus under the name of OP-1®. Both molecules mediate the process of osteoblast differentiation. BMP-2 is capable of stimulating immature mesenchymal cells to form into bone, while BMP-7 has been shown to be capable of stimulating cartilage growth. The bone graft substitute market competes with both the growth factor market, which is currently only comprises INFUSE®, and the stem cell graft market. Due to the declining usage of INFUSE®, the use of bone graft substitute use has increased. The rise of cell therapy products, including platelet-rich-plasma and bone marrow concentrate, has also aided the growth of the bone graft substitute market, especially in the segments for demineralized bone matrices and synthetic grafts. Platelet-rich plasma provides growth factors when a graft is soaked in it; bone marrow concentrate provides stem cells. This complementary use allows bone graft substitutes to better compete with the growth factors and stem cell grafts.

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

RESEARCH METHODOLOGY

  • 1.1. RESEARCH SCOPE
  • 1.2. IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

EUROPEAN COUNTRY PROFILES

  • 2.1. INTRODUCTION
    • 2.1.1. Population
    • 2.1.2. GDP per Capita
    • 2.1.3. Price Index
  • 2.2. GERMANY
  • 2.3. FRANCE
  • 2.4. UNITED KINGDOM
  • 2.5. ITALY
  • 2.6. SPAIN
  • 2.7. BENELUX
  • 2.8. SCANDINAVIA
  • 2.9. AUSTRIA
  • 2.10. SWITZERLAND
  • 2.11. PORTUGAL

EUROPEAN BONE MORPHOGENETIC PROTEIN GROWTH FACTOR THERAPY MARKET

  • 3.1. INTRODUCTION
  • 3.2. MARKET ANALYSIS AND FORECAST
  • 3.3. MARKET DRIVERS AND LIMITERS
    • 3.3.1. Market Drivers
    • 3.3.2. Market Limiters
  • 3.4. COMPETITIVE ANALYSIS

U.S. BONE MORPHOGENETIC PROTEIN GROWTH FACTOR THERAPY MARKET

  • 4.1. MARKET ANALYSIS AND FORECAST
  • 4.2. DRIVERS AND LIMITERS
    • 4.2.1. Market Drivers
    • 4.2.2. Market Limiters
  • 4.3. COMPETITIVE ANALYSIS

ABBREVIATIONS

Back to Top